Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib as First-Line Treatment in EGFR-Mutant Advanced NSCLC
NCT00339586Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00339586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00339586.